摘要
目的探讨白血病患者应用阿糖胞苷治疗的有效性以及安全性。方法选取我院收治的白血病复发患者104例,随机分为两组,对照组应用化疗诱导治疗,研究组联合应用阿糖胞苷治疗。观察对比两组白血病患者的临床疗效、不良反应、无复发生存率及生存率、治疗前后凝血功能指标变化。结果研究组临床疗效显著高于对照组(P<0.05),不良反应发生率显著低于对照组(P<0.05),各阶段无复发生存率及生存率均显著高于对照组(P<0.05),治疗1 d后FIB显著低于对照组(P<0.05),PT、TT及APTT显著高于对照组(P<0.05)。结论临床对白血病复发患者联合应用阿糖胞苷的疗效较理想,能显著延长无复发生存时间及生存率,值得推广应用。
Objective To investigate the efficacy and safety of cytarabine in the treatment of leukemia patients.Methods 104 cases of leukemia relapsed in our hospital.The leukemia patients in two groups were treated with chemical induction therapy,and those in study group were added with cytarabine.The clinical effect,adverse reaction,non recurrent survival rate and survival rate of two groups of leukemia patients were observed and compared,as well as the changes of blood coagulation function before and after treatment.Results The clinical efficacy of leukemia patients in the study group was better than that of the control group(P<0.05).The adverse reactions of the leukemia patients in the study group were less than that of the control group(P<0.05).The non recurrent survival rate and overall survival rate of the leukemia patients in the study group were higher than those of the control group(P<0.05).After treatment of one day,the FIB of the study group was lower than that of the control group(P<0.05),but the PT,TT and APTT were higher than those of the control group(P<0.05).Conclusion The combination application of cytarabine had good clinical effect in the treatment of patients with recurrent leukemia.It could significantly prolong the non recurrent survival time and survival rate of leukemia patients.It is worth applying and popularizing.
作者
马晓静
冀林华
耿惠
罗伟
殷玉娟
MA Xiaojing;JI Linhua;GENG Hui;LUO Wei;YIN Yujuan(Department of Hematology,Affiliated Hospital of Qinghai University,Xining,Qinghai,810001,China)
出处
《肿瘤药学》
CAS
2018年第3期396-399,共4页
Anti-Tumor Pharmacy
基金
青海大学附属医院中青年科技基金项目(ASRF-2015-YB-03)
关键词
白血病
阿糖胞苷
临床疗效
安全性
Keywords leukemia
Cytarabine
Clinical efficacy
Safety
